Wearable ECG Systems with Automatic Vagus Nerve Stimulation
Summary
The USPTO published patent application US20260090757A1 by inventor David C. Shaw for wearable electrocardiogram (ECG) monitoring systems with automatic anti-arrhythmia capabilities. The application covers ECG systems that record from ears, fingers, or toes and include transcutaneous auricular vagus nerve stimulation (taVNS) to automatically detect and treat serious cardiac arrhythmias. Filing date was September 18, 2025.
What changed
This patent application describes wearable ECG monitoring systems configured to record cardiac data from auricular, finger, or toe locations, with processing units designed to detect serious cardiac arrhythmias. The anti-arrhythmia systems include transcutaneous auricular vagus nerve stimulation (taVNS) units that can automatically deliver pre-determined electric stimuli to the vagus nerve when arrhythmias are detected. The electrodes and stimulation components are housed in flexible elastic material suitable for self-installation and ambulatory use.
This is a patent application publication, not a regulatory action. It does not create compliance obligations or deadlines. Medical device companies and healthcare providers developing wearable cardiac monitoring or neuromodulation products should review the claims to assess potential patent landscape implications for their own product development activities.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
WEARABLE ELECTROCARDIOGRAM (ECG) MONITORING SYSTEMS AND AUTOMATIC ANTI-ARRHYTHMIA SYSTEMS
Application US20260090757A1 Kind: A1 Apr 02, 2026
Inventors
David C. Shaw
Abstract
Wearable electrocardiogram (ECG) systems configured to record ECG from ears (auricular ECG systems), fingers (ear-finger or finger-finger ECG systems) or toes, comprising a processing unit configured to analyze the ECG data to detect serious cardiac arrhythmias or impending serious cardiac arrhythmia. Automatic anti-arrhythmia systems comprise one of the ECG systems and a transcutaneous auricular vagus nerve stimulation (taVNS) unit. When serious cardiac arrythmias are detected, the anti-arrhythmia systems may automatically send pre-determined electric stimuli to a vagus nerve to alleviate or stop the cardiac arrhythmias. The ECG electrodes and the stimulating electrode of the taVNS unit are located on a surface of a housing structure made of flexible elastic and adaptable material such that these electrodes will be naturally and snugly contacting the wearer's skin. These wearable ECG and anti-arrhythmia systems are suitable for easy self-installation, self-removal and daily ambulatory use.
CPC Classifications
A61B 5/363 A61B 5/256
Filing Date
2025-09-18
Application No.
19332747
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Diagnosis & Surgery (A61B)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Diagnosis & Surgery (A61B) publishes new changes.